![]() |
市場調查報告書
商品編碼
1771617
美國創傷性腦損傷生物標記市場規模、佔有率、趨勢分析報告:按類型、樣本類型、應用、最終用途、細分預測,2025-2033U.S. Traumatic Brain Injury Biomarkers Market Size, Share & Trends Analysis Report By Type (Protein Biomarkers, Genetic Biomarkers, Metabolomic Biomarkers), By Sample Type, By Application, By End Use, And Segment Forecasts, 2025 - 2033 |
美國創傷性腦損傷生物標記市場規模預計在 2024 年為 4.096 億美元,預計到 2033 年將達到 18.5473 億美元,2025 年至 2033 年的複合年成長率為 18.8%。
由於對兒科 TBI 診斷的需求不斷增加、對腦損傷的認知和資金不斷增加以及學術界和工業界之間的合作不斷加速,美國創傷性腦損傷 (TBI) 生物標記市場正在經歷顯著成長。
創傷性腦損傷 (TBI) 是指頭部受到意外撞擊,可能導致輕度至重度神經損傷,甚至死亡。根據美國腦損傷協會 (Brain Injury Association of America) 2025 年的報告,美國約有 1,140 萬 40 歲及以上人士因創傷性腦損傷 (TBI) 而失去意識,目前處於殘疾狀態。此外,每年約有 290 萬例與 TBI 相關的急診就診,凸顯了腦損傷帶來的沉重醫療負擔。
兒童和青少年特別容易受到因跌倒、運動傷害和事故造成的 TBI 的影響。在美國,每年約有 50 萬次兒童 TBI 急診就診。雖然兒童死亡率總體較低,約佔所有 TBI 相關死亡人數的 5%,但如果考慮到生命損失年數和殘疾生活年數,其更廣泛的影響就顯而易見。這些長期影響在兒童中明顯大於成人,凸顯了兒童 TBI 對公共衛生和生活品質造成的嚴重且持久的負擔。兒科保健提供者擴大轉向生物標記診斷,以便做出更安全、更快速的決策,並減少不必要的輻射暴露,尤其是來自電腦斷層掃描的輻射暴露。
基於血液的生物標記提供了一種非侵入性且客觀的方法來評估年輕患者的損傷風險和嚴重程度。瑞士和西班牙知名醫院於2024年6月進行的一項合作研究發現,血液生物標記可以顯著改善兒童輕度創傷性腦損傷 (mTBI) 的診斷和治療。這項由ABCDx、日內瓦大學和Vall d'Hebron醫院參與的多中心研究強調了血液生物標記在準確區分有無顱內損傷 (ICI) 兒童方面的潛力。這可以減少不必要的電腦斷層掃描,縮短住院觀察期,並提高兒科mTBI護理的效率。
研究型大學、生物技術公司和醫療保健提供者之間的緊密合作正在推動生物標記的檢驗和商業化。研究機構正在與生物技術和診斷公司合作,將實驗室發現轉化為臨床試驗。新的臨床試驗在推動TBI診斷和治療方面具有巨大潛力。這些臨床試驗專注於評估創新的診斷工具和治療方法,可以為更有效、更及時的干涉鋪平道路,並有可能改變急性和長期TBI管理中的患者預後。此類夥伴關係有助於加速臨床試驗、FDA申報和市場准入。此外,數據資源和生物樣本庫的共用支持縱向研究,從而提高生物標記的可靠性。美國生態系統透過公私合作促進創新的能力,是擴大TBI生物標記市場的主要競爭優勢。
醫療、社會和製度因素的共同作用,推動了美國市場對TBI生物標記的資金投入增加。社會對TBI長期影響的認知不斷提高,尤其是在體育和軍事領域,這推動了對更準確、更及時的診斷工具的需求。傳統的影像學檢查通常無法檢測到輕微或早期損傷,因此需要基於生物標記的解決方案,以提供客觀、快速和非侵入性的評估。 2024年2月,美國指導醫學研究計畫 (CDMRP) 和美國醫學研究與發展司令部 (USAMRDC) 等政府機構將增加創傷性腦損傷和心理健康研究計畫 (TBIPHRP) 等計畫的投資。這些計畫旨在推動早期發現、治療和預防策略,同時應對TBI的心理影響。這些資金的湧入,加上商業化潛力和日益成長的創業投資興趣,正在加速創新,重塑美國TBI生物標記領域的格局。
The U.S. traumatic brain injury biomarkers market size was estimated at USD 409.60 million in 2024, is projected to reach 1,854.73 million by 2033, and is forecasted to grow at a CAGR of 18.8% from 2025 to 2033. The U.S. traumatic brain injury (TBI) biomarkers market is expanding significantly due to increasing demand for pediatric TBI diagnosis, growing awareness and funding related to brain injury, and accelerating collaboration between academic institutions and industry.
TBI refers to an unintentional impact to the head that can lead to outcomes ranging from mild impairment to severe neurological damage or even death. According to a report by the Brain Injury Association America, 2025, the U.S. reported approximately 11.4 million individuals over the age of 40 who experienced a traumatic brain injury (TBI) resulting in loss of consciousness are currently living with a disability. In addition, around 2.9 million TBI-related emergency department visits are reported each year, indicating the significant healthcare burden associated with brain injuries.
Children and adolescents are particularly vulnerable to TBIs from falls, sports injuries, and accidents, yet symptoms can be subtle or delayed. Every year in the U.S., pediatric TBI leads to an estimated 500,000 emergency department visits. While children have a lower overall mortality rate, accounting for about 5% of all TBI-related deaths, the broader impact is more evident when considering years of life lost and years lived with disability. These long-term effects are notably greater in children than in adults, with the serious and lasting burden pediatric TBI poses on public health and quality of life. Pediatric care providers are increasingly turning to biomarker diagnostics to make safer and faster decisions, especially to reduce unnecessary radiation exposure from CT scans.
Blood-based biomarkers offer a non-invasive, objective method to assess injury risk and severity in young patients. A collaborative study conducted in June 2024, by renowned hospitals in Switzerland and Spain, discovered potential blood biomarkers that could significantly improve the diagnosis and management of mild traumatic brain injury (mTBI) in children. This multi-center research, involving ABCDx, the University of Geneva, and Vall d'Hebron Hospital, highlighted the potential of these blood biomarkers to accurately differentiate children with intracranial injuries (ICI) from those without. This reduced unnecessary CT scans and shorter hospital observation periods, improving efficiency in pediatric mTBI care.
Strong collaboration between research universities, biotech companies, and healthcare providers is advancing biomarker validation and commercialization. Institutions are working with biotech and diagnostics companies to translate laboratory discoveries into clinical tests. A new clinical trial holds significant promise for advancing the diagnosis and treatment of TBI. Focused on evaluating innovative diagnostic tools or therapeutic approaches, this trial could pave the way for more effective and timely interventions, potentially transforming patient outcomes in acute and long-term TBI management. These partnerships help accelerate clinical trials, FDA submissions, and market entry. In addition, shared data resources and biobanks support longitudinal studies that strengthen biomarker credibility. The U.S. ecosystem's ability to foster innovation through public-private-academic collaboration is a major competitive advantage in expanding the TBI biomarker market.
A convergence of medical, social, and institutional factors drives rising funding for TBI biomarkers in the U.S. market. Growing public awareness of TBIs' long-term consequences, particularly in sports and military populations, has amplified demand for more accurate and timely diagnostic tools. Traditional imaging often falls short in detecting mild or early-stage injuries, creating a critical need for biomarker-based solutions to provide objective, rapid, and non-invasive assessments. In February 2024, government agencies such as the Congressionally Directed Medical Research Programs (CDMRP) and the U.S. Army Medical Research and Development Command (USAMRDC) have increased investments in initiatives like the Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP). These efforts aim to advance early detection, treatment, and prevention strategies, while also addressing the psychological effects of TBI. Coupled with growing commercialization potential and venture capital interest, this influx of funding is accelerating innovation and reshaping the TBI biomarker landscape in the United States.
U.S. Traumatic Brain Injury Biomarkers Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented U.S. traumatic brain injury biomarkers market report based on type, sample type, application, and end use: